Abemaciclib + Letrozole
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Low Grade Serous Ovarian Carcinoma
Conditions
Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor
Trial Timeline
Nov 30, 2023 → Jan 1, 2028
NCT ID
NCT05872204About Abemaciclib + Letrozole
Abemaciclib + Letrozole is a phase 2 stage product being developed by Eli Lilly for Low Grade Serous Ovarian Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05872204. Target conditions include Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05872204 | Phase 2 | Recruiting |
| NCT04393285 | Phase 2 | Active |
Competing Products
20 competing products in Low Grade Serous Ovarian Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [203Pb]VMT-α-NET | Perspective Therapeutics | Phase 1 | 25 |
| azenosertib | Zentalis Pharmaceuticals | Phase 2 | 44 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 44 |
| DS-1001b | Daiichi Sankyo | Phase 2 | 52 |
| Rabeprazole Sodium | Eisai | Pre-clinical | 23 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 52 |
| Pirtobrutinib + Mosunetuzumab | Eli Lilly | Phase 2 | 52 |
| Pembrolizumab + Pemetrexed + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| DSP-0390 | Sumitomo Pharma | Phase 1 | 33 |
| Mirvetuximab soravtansine + Carboplatin | AbbVie | Phase 2 | 52 |
| Mirvetuximab Soravtansine | AbbVie | Phase 2 | 52 |
| Acalabrutinib + Obinutuzumab | AstraZeneca | Phase 2 | 52 |
| Olaparib Pill + AZD6738 | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Efineptakin alfa + Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel | Merck | Phase 2 | 52 |
| Cilengitide | Merck | Phase 2 | 52 |
| Avelumab | Merck | Phase 2 | 52 |
| Human Papillomavirus vaccine | Merck | Phase 2 | 52 |